Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + apatinib + camrelizumab
- Development stage
- Phase 2
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
irinotecan liposome + apatinib + camrelizumab is an investigational combination therapeutic regimen being evaluated by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School for the treatment of advanced solid tumors. The regimen integrates three distinct therapeutic modalities: chemotherapy via a liposomal formulation of irinotecan (a topoisomerase I inhibitor), anti-angiogenic therapy with apatinib (a selective VEGFR-2 tyrosine kinase inhibitor), and immunotherapy with camrelizumab (an anti-PD-1 monoclonal antibody). In clinical trials, this combination is typically administered following stereotactic body radiotherapy (SBRT) to exploit potential synergistic effects, such as the abscopal effect and enhanced drug delivery through vascular normalization. The treatment is aimed at patients who have progressed on or are ineligible for standard-of-care therapies across various solid tumor types, including gastrointestinal and lung cancers.
- Other names
- Radiotherapy + irinotecan liposome + apatinib + camrelizumabIrinotecan liposome + apatinib + camrelizumab
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on irinotecan liposome + apatinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + apatinib + camrelizumab.